 12. Subjects being enrolled to receive paclitaxel plus carboplatin treatment must have neuropathic function sensory and motor less than or equal to Grade 2 according to the National Cancer Institutes Common Terminology Criteria for Adverse Events CTCAE v4.03 2010 